Tesamorelin
Price range: £22.99 through £90.99
Tesamorelin
Hormonal — GHRH Analogue Tesamorelin
An FDA-approved synthetic GHRH analogue (Egrifta®) for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
It is unique among GH-axis peptides in having genuine regulatory approval, and its clinical data provides high-quality evidence for its mechanism and effects on body composition.
- Approval: FDA 2010 (Egrifta®)
- Indication: HIV lipodystrophy — visceral fat
- Half-Life: ~26 minutes
Tesamorelin
Mechanism of Action
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile GH secretion and downstream IGF-1 elevation — producing a physiological GH profile rather than supraphysiological spikes.
Visceral Fat Reduction
Clinical trials in HIV-associated lipodystrophy demonstrate 15–20% reductions in visceral adipose tissue volume as measured by CT scan, with effects on trunk fat exceeding those on subcutaneous fat.
Cognitive & Metabolic Research
Beyond body composition, pilot trials suggest potential benefits in mild cognitive impairment in older adults, with ongoing research into GH axis restoration as a cognitive intervention.
Research compound only — not licensed for human consumption or therapeutic use. Sold strictly for laboratory research purposes.
Vials (Peptides)
Pre-mixed Pens (Peptides)
Nasal Spray (Peptides)
Cream (Peptides)
Reviews
There are no reviews yet.